← Leaderboards
Anindita Das
Virginia Commonwealth University
$3,017,498
Attributed
$6,949,498
Total exposure
5
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2016–25$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,949,498 · 5
By mechanism
R01$4,205,992 · 2
R44$1,993,505 · 1
R43$750,001 · 2
Top collaborators
- Rakesh C. Kukreja8 shared
- Fadi N Salloum4 shared
- Cathy A Swindlehurst4 shared
Most similar at Virginia Commonwealth University
Same institution · by research overlap
- Hisashi Harada$3,277,011
- Joseph William Landry$2,951,878
- David A. Gewirtz$3,700,163
- Paul Dent$11,860,656
- Fadi N Salloum$8,358,104
Others in their field
Top investigators on “Cardiomyopathies”
- Chanza Baytop · Westat, Inc.$271,217,917
- Paula Darby Lipman · Westat, Inc.$52,512,411
- Joseph C Wu · Stanford University$31,439,487
- Ju Chen · University Of California, San Diego$28,045,539
- David Alan Kass · Johns Hopkins University$21,891,376
- Joshua M Hare · Johns Hopkins University$21,076,422
Research focus
CardiomyopathiesHeartIn VivoPreventMortalityHeart FailureNovel TherapeuticsCardioprotectionFrap1 GeneCardiac MyocytesPharmaceutical PreparationsDiabeticSignal TransductionCessation Of LifeMyocardial DysfunctionCardiacIn VitroClinically RelevantInjuryLeadCardiovascular DiseasesDoseBreast Cancer TreatmentCardiotoxicity
Grant awards (12)
Novel Strategy of PDE5-mTOR Inhibition in Attenuation of Cancer Drug Cardiotoxicity$524,060
R01 · FY2025 · HL · contact PI
Novel Strategy of PDE5-mTOR Inhibition in Attenuation of Cancer Drug Cardiotoxicity$513,579
R01 · FY2024 · HL · contact PI
Novel small molecules for protection against doxorubicin cardiotoxicity in TNBC$930,592
R44 · FY2023 · HL
Novel Strategy of PDE5-mTOR Inhibition in Attenuation of Cancer Drug Cardiotoxicity$547,243
R01 · FY2023 · HL
Novel small molecules for protection against doxorubicin cardiotoxicity in TNBC$1,062,913
R44 · FY2022 · HL
Novel Strategy of PDE5-mTOR Inhibition in Attenuation of Cancer Drug Cardiotoxicity$556,570
R01 · FY2022 · HL
Novel Therapy for Protection against Diabetes and its Complications in Ischemic Heart Disease$375,000
R43 · FY2021 · HL
Cardioprotection with mTOR Inhibition$516,135
R01 · FY2019 · HL
Novel small molecules for protection against doxorubicin cardiotoxicity in TNBC$375,001
R43 · FY2019 · HL
Cardioprotection with mTOR Inhibition$516,135
R01 · FY2018 · HL
Cardioprotection with mTOR Inhibition$516,135
R01 · FY2017 · HL
Cardioprotection with mTOR Inhibition$516,135
R01 · FY2016 · HL